NCT04387539View on ClinicalTrials.gov

ٍٍSofosbuvir/Simeprevir/Daclatasvir/Ribavirin and HCV Genotype 4-infected Egyptian Experienced Participants

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

March 1, 2017

Primary Completion Date

October 31, 2017

Study Completion Date

October 31, 2017

Conditions
Chronic Hepatitis C Virus Infection
Interventions
DRUG

SOF/SMV/DCV/RBV

SOF was given orally at a dose of 400 mg/day DCV was given orally at a dose of 60 mg/day SMV was given orally at a dose of 150 mg/day. RBV was given in a total daily oral dose of 600 mg/day up to 1,200 mg/day according to the participant's weight and tolerability.

Trial Locations (1)

Unknown

Health Administration at Beni-Seuf, Bani Sweif

All Listed Sponsors
lead

Beni-Suef University

OTHER

NCT04387539 - ٍٍSofosbuvir/Simeprevir/Daclatasvir/Ribavirin and HCV Genotype 4-infected Egyptian Experienced Participants | Biotech Hunter | Biotech Hunter